BioHarvest Launches Single-Dose VINIA Daily Chews Expanding Consumer Product Offering

BioHarvest Sciences Inc, a company at the forefront of Botanical Synthesis, has expanded its portfolio with the launch of single-dose VINIA Daily Chews. This new product format aims to broaden the company's reach and demonstrate the versatility of its proprietary technology.

VINIA, BioHarvest's first consumer product, is a red-grape cell composition developed through the company’s Botanical Synthesis platform. The new daily chews, available in individual packaging, deliver 400 mg of VINIA along with 6 mg of piceid resveratrol, a daily dosage clinically shown to increase arterial dilation and improve blood flow. The chews are designed to complement the existing VINIA portfolio, offering consumers a convenient alternative to traditional capsules.

Dr. Zaki Rakib, CEO of BioHarvest Sciences, emphasized the strategic importance of the new product. "VINIA is not just our first consumer product; it is a core commercial asset and a live validation of our platform. By expanding formats, we are broadening the demographics and usage occasions for VINIA, while also providing a practical example of the flexibility and commercial potential of Botanical Synthesis for our CDMO partners."

The launch of the single-dose VINIA Daily Chews is part of BioHarvest's broader strategy to unlock more value from its proprietary compositions. The company is leveraging its technology to develop and manufacture plant-based compositions without the need to grow the underlying plants. This approach allows for consistent, full-spectrum plant compound compositions that can be incorporated into a range of consumer products.

According to MarketsandMarkets, the global gummy/chewable supplements market is estimated at approximately $24.4 billion in 2025 and is projected to grow at a 14.4% CAGR through 2030. This growth reflects strong consumer demand for convenient formats that can reach demographics beyond traditional capsule users. BioHarvest is positioning itself to capitalize on this trend by expanding VINIA into additional formats, including the new single-dose chews.

The new product format is designed to fit a broader set of daily habits, potentially increasing customer engagement and retention. Early market feedback indicates strong customer engagement and retention relative to expectations for a new delivery form. BioHarvest believes that the chewable format aligns well with the broader demographic mix the company is now reaching through expanded advertising, supporting the conversion into a daily habit and deeper franchise value.

Beyond convenience, the chewable format also provides an opportunity to explore oral transmucosal delivery of piceid resveratrol and grape polyphenols. Published research on transmucosal resveratrol delivery provides a scientific basis for exploring how delivery format may affect the absorption and systemic exposure of resveratrol and other grape-derived polyphenols. Research has shown that compounds delivered through the tissues of the mouth may partially bypass gastrointestinal degradation and first-pass liver metabolism, potentially influencing the timing and extent of systemic exposure.

VINIA Daily Chews are now available for purchase on the company’s website, www.vinia.com. The product is part of BioHarvest's ongoing efforts to demonstrate the commercial versatility of its Botanical Synthesis platform and to expand the addressable market for VINIA. By offering a natural, non-GMO composition in a versatile powder format, BioHarvest is creating opportunities for incorporation into a range of consumer products, while also providing a commercial example for its CDMO partners.

In summary, the launch of single-dose VINIA Daily Chews marks a significant step in BioHarvest's mission to provide natural wellness at scale. The product expansion is designed to unlock more value from VINIA, broaden the company's reach, and demonstrate the potential of its proprietary technology in the consumer goods market.